BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Short Interest Down 58.3% in March

BriaCell Therapeutics Corp. (NASDAQ:BCTXW) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 1,500 shares, a decline of 58.3% from the February 28th total of 3,600 shares. Based on an average daily volume of 66,600 shares, the short-interest ratio is presently 0.0 days.

BriaCell Therapeutics Price Performance

BCTXW stock opened at $0.09 on Friday. The business has a 50 day simple moving average of $0.12 and a 200-day simple moving average of $0.24. BriaCell Therapeutics has a twelve month low of $0.07 and a twelve month high of $1.39.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.